Profile data is unavailable for this security.
About the company
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). The Company’s product candidates include NAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist.
- Revenue in USD (TTM)0.00
- Net income in USD-43.16m
- Incorporated2004
- Employees40.00
- LocationAnavex Life Sciences Corp630 5Th Avenue, 20Th FloorNEW YORK 10111United StatesUSA
- Phone+1 (800) 689-3939
- Websitehttps://www.anavex.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aquestive Therapeutics Inc | 50.58m | -7.87m | 288.15m | 135.00 | -- | -- | -- | 5.70 | -0.1437 | -0.1437 | 0.7691 | -1.55 | 0.8836 | 3.32 | 7.68 | 374,688.90 | -13.75 | -76.63 | -27.78 | -123.85 | 58.82 | 64.24 | -15.56 | -102.95 | 1.87 | -- | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
| CorMedix Inc | 0.00 | -46.34m | 288.93m | 82.00 | -- | 4.12 | -- | -- | -0.9172 | -0.9172 | 0.00 | 1.28 | 0.00 | 0.00 | -- | 0.00 | -64.32 | -54.84 | -73.33 | -62.32 | -- | 6.18 | -- | -18,323.42 | 6.78 | -- | 0.00 | -- | -100.00 | -- | -56.02 | -- | 46.27 | -- |
| Inovio Pharmaceuticals Inc | 832.01k | -135.12m | 290.02m | 122.00 | -- | 2.22 | -- | 348.58 | -6.12 | -6.12 | 0.0375 | 5.15 | 0.0032 | -- | 0.9778 | 6,819.75 | -52.02 | -59.52 | -71.11 | -71.29 | -- | -- | -16,239.87 | -4,097.36 | -- | -- | 0.125 | -- | -91.89 | -51.33 | 51.71 | -- | -31.22 | -- |
| Enanta Pharmaceuticals Inc | 73.62m | -138.24m | 290.68m | 145.00 | -- | 1.51 | -- | 3.95 | -6.56 | -6.56 | 3.50 | 9.07 | 0.1897 | -- | 4.79 | 507,737.90 | -35.63 | -14.56 | -40.03 | -15.62 | -- | -- | -187.77 | -54.96 | -- | -- | 0.0074 | -- | -8.07 | -17.45 | -9.91 | -- | 24.89 | -- |
| Black Diamond Therapeutics Inc | 0.00 | -82.44m | 292.59m | 54.00 | -- | 2.46 | -- | -- | -1.92 | -1.92 | 0.00 | 2.26 | 0.00 | -- | -- | 0.00 | -52.37 | -40.29 | -58.91 | -43.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.57 | -- | -15.37 | -- |
| XOMA Corp | 4.76m | -46.30m | 294.83m | 13.00 | -- | 3.29 | -- | 61.97 | -4.04 | -4.04 | 0.4148 | 7.72 | -- | -- | -- | 366,000.00 | -- | -4.55 | -- | -4.94 | -- | -- | -858.15 | -31.87 | -- | -- | 0.583 | -- | -21.06 | -2.13 | -105.10 | -- | 23.16 | -- |
| Verrica Pharmaceuticals Inc | 5.12m | -67.00m | 295.46m | 100.00 | -- | 14.95 | -- | 57.66 | -1.46 | -1.46 | 0.113 | 0.466 | 0.0811 | -- | 2.09 | 51,240.00 | -106.07 | -55.75 | -126.60 | -78.33 | 85.44 | -- | -1,307.48 | -754.94 | 4.49 | -51.74 | 0.6914 | -- | -43.27 | -- | -173.59 | -- | 5.65 | -- |
| Procaps Group SA | 414.10m | 52.20m | 295.60m | 5.50k | 5.03 | 7.51 | 4.24 | 0.7138 | 0.5209 | 0.5209 | 4.16 | 0.3491 | 0.854 | 1.87 | 3.38 | 75,290.18 | 10.77 | -- | 19.01 | -- | 55.04 | -- | 12.61 | -- | 0.9861 | -- | 0.8829 | -- | 0.0434 | -- | 142.18 | -- | -- | -- |
| Anavex Life Sciences Corp | 0.00 | -43.16m | 299.71m | 40.00 | -- | 2.21 | -- | -- | -0.5357 | -0.5357 | 0.00 | 1.65 | 0.00 | -- | -- | 0.00 | -29.12 | -40.04 | -31.88 | -43.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 0.9857 | -- | -- | -- |
| Medifast Inc | 897.81m | 67.76m | 299.96m | 634.00 | 4.44 | 1.43 | 3.70 | 0.3341 | 6.20 | 6.20 | 82.15 | 19.29 | 2.88 | 3.37 | -- | 1,416,106.00 | 21.71 | 41.25 | 32.62 | 69.38 | 73.15 | 73.20 | 7.55 | 10.06 | 2.25 | -- | 0.00 | 49.18 | -32.94 | 16.43 | -30.75 | 12.25 | 5.59 | 17.72 |
| Adaptimmune Therapeutics PLC - ADR | 60.28m | -113.87m | 304.12m | 449.00 | -- | 6.84 | -- | 5.05 | -0.5218 | -0.5218 | 0.2995 | 0.1739 | 0.1972 | -- | 14.60 | 134,256.10 | -37.24 | -41.19 | -48.02 | -48.21 | -- | -- | -188.90 | -714.26 | -- | -- | 0.00 | -- | 122.05 | 0.2595 | 31.18 | -- | 0.7202 | -- |
| Lyra Therapeutics Inc | 1.56m | -62.68m | 308.27m | 88.00 | -- | 3.30 | -- | 197.87 | -1.32 | -1.32 | 0.0313 | 1.56 | 0.0123 | -- | -- | 17,704.54 | -49.63 | -58.01 | -57.37 | -68.69 | -- | -- | -4,023.11 | -6,235.31 | -- | -- | 0.00 | -- | 14.31 | 4.60 | -13.39 | -- | 95.14 | -- |
| Fibrobiologics Inc | 0.00 | -19.06m | 308.54m | 10.00 | -- | 245.60 | -- | -- | -0.9149 | -0.9149 | 0.00 | 0.0384 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -60.47 | 0.1012 | -- | -- | -- | -272.15 | -- | -- | -- |
| Cerus Corp | 186.80m | -37.49m | 308.77m | 288.00 | -- | 5.75 | -- | 1.65 | -0.2086 | -0.2086 | 1.04 | 0.2905 | 0.8984 | 2.03 | 5.34 | 648,600.70 | -18.11 | -25.99 | -32.81 | -40.62 | 62.54 | 61.90 | -20.15 | -35.81 | 1.55 | -2.91 | 0.5989 | -- | -0.8061 | 19.69 | 12.37 | -- | 32.07 | -- |
| Organogenesis Holdings Inc | 433.14m | 4.95m | 310.11m | 862.00 | 63.93 | 1.11 | 15.27 | 0.716 | 0.0368 | 0.0368 | 3.27 | 2.12 | 0.9526 | 4.02 | 5.05 | 502,482.60 | 1.09 | 5.46 | 1.31 | 6.90 | 75.42 | 74.94 | 1.14 | 4.81 | 2.44 | 9.05 | 0.1989 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
Data as of May 01 2024. Currency figures normalised to Anavex Life Sciences Corp's reporting currency: US Dollar USD
23.07%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2023 | 5.96m | 7.26% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 4.16m | 5.06% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 3.64m | 4.44% |
| Geode Capital Management LLCas of 31 Dec 2023 | 1.67m | 2.03% |
| NWAM LLCas of 31 Dec 2023 | 798.29k | 0.97% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 739.64k | 0.90% |
| Susquehanna Financial Group LLLPas of 31 Dec 2023 | 721.35k | 0.88% |
| Charles Schwab Investment Management, Inc.as of 31 Dec 2023 | 622.31k | 0.76% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 330.28k | 0.40% |
| SG Americas Securities LLCas of 31 Dec 2023 | 307.57k | 0.38% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
